Read by QxMD icon Read


J Jaime Caro, John E Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J McGuire, Erik Nord, Michael Schlander
The economic evaluation of new health technologies to assess whether the value of the expected health benefits warrants the proposed additional costs has become an essential step in making novel interventions available to patients. This assessment of value is problematic because there exists no natural means to measure it. One approach is to assume that society wishes to maximize aggregate health, measured in terms of quality-adjusted life-years (QALYs). Commonly, a single 'cost-effectiveness' threshold is used to gauge whether the intervention is sufficiently efficient in doing so...
November 9, 2018: PharmacoEconomics
Vikas Soekhai, Esther W de Bekker-Grob, Alan R Ellis, Caroline M Vass
OBJECTIVES: Discrete choice experiments (DCEs) are increasingly advocated as a way to quantify preferences for health. However, increasing support does not necessarily result in increasing quality. Although specific reviews have been conducted in certain contexts, there exists no recent description of the general state of the science of health-related DCEs. The aim of this paper was to update prior reviews (1990-2012), to identify all health-related DCEs and to provide a description of trends, current practice and future challenges...
November 3, 2018: PharmacoEconomics
Thananan Rattanachotphanit, Chulaporn Limwattananon, Onanong Waleekhachonloet, Phumtham Limwattananon, Kittisak Sawanyawisuth
OBJECTIVE: The objective of this study was to assess the cost effectiveness of direct-acting oral anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a HAS-BLED score of 3. METHODS: Total costs (US$) in 2017 and quality-adjusted life-years were estimated over 20 years using a Markov model. A base-case analysis was conducted under a societal perspective, which included direct healthcare, non-healthcare and indirect costs in Thailand...
November 2, 2018: PharmacoEconomics
Eytan Stein, Jipan Xie, Emilie Duchesneau, Subrata Bhattacharyya, Umakanth Vudumula, Briana Ndife, Gaetano Bonifacio, Annie Guerin, Nanxin Li, George Joseph
OBJECTIVES: The aim of this study was to assess the cost effectiveness of midostaurin + cytarabine + daunorubicin (midostaurin arm) versus placebo + cytarabine + daunorubicin (placebo arm) in the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) who are eligible for standard cytarabine + daunorubicin chemotherapy, from a US third-party payer perspective. METHODS: A lifetime partitioned survival model with four health states (active disease, complete remission [CR], relapse, and death) was constructed...
November 1, 2018: PharmacoEconomics
Andrea Marcellusi, Raffaella Viti, Loreta A Kondili, Stefano Rosato, Stefano Vella, Francesco Saverio Mennini
OBJECTIVE: We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy. METHODS: A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature...
October 30, 2018: PharmacoEconomics
Edward T Chiyaka, Van T Nghiem, Lu Zhang, Abhishek Deshpande, Patricia Dolan Mullen, Phuc Le
BACKGROUND: Herpes zoster (HZ) is one of the most common diseases among adults. Its reactivation is characterized by a severe and painful complication. In addition to the existing herpes zoster vaccine (ZVL), the FDA approved a new adjuvanted subunit zoster vaccine (RZV) in 2017 for use in adults aged 50 years and older. Several studies have assessed the cost-effectiveness of ZVL, many of which were conducted before the long-term vaccine  efficacy data was available in 2014. OBJECTIVE: Our objectives were to (i) summarize and compare the cost-effectiveness analyses (CEAs) of ZVL conducted before and after 2014, (ii) summarize the CEAs of RZV, and (iii) critically assess the cost-effectiveness models and identify key parameters to consider for future CEAs of RZV...
October 27, 2018: PharmacoEconomics
Tracey-Lea Laba, Helen K Reddel, Nicholas J Zwar, Guy B Marks, Elizabeth Roughead, Anthony Flynn, Michele Goldman, Aine Heaney, Kirsty Lembke, Stephen Jan
BACKGROUND: In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta2 -agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. METHODS: We conducted a discrete choice experiment (DCE) in a nationally representative sample of adults (n = 792) and parents of children (n = 609) with asthma...
October 27, 2018: PharmacoEconomics
James Love-Koh, Alison Peel, Juan Carlos Rejon-Parrilla, Kate Ennis, Rosemary Lovett, Andrea Manca, Anastasia Chalkidou, Hannah Wood, Matthew Taylor
The article The Future of Precision Medicine: Potential Impacts for Health Technology Assessment written by James Love‑Koh, Alison Peel Juan, Carlos Rejon‑Parrilla, KateAnastasia Chalkidou, Hannah Wood, Matthew Taylor was originally published electronically on the publisher's internet portal (currently Springer Link) on [13th July, 2018] with incorrect spelling of the co-author "Juan Carlos Rejon-Parilla". The correct spelling is "Juan Carlos Rejon-Parrilla".
October 26, 2018: PharmacoEconomics
Sarah Davis, Rachid Rafia, Christopher Carroll, Jean Hamilton, Munira Essat
The National Institute for Health and Care Excellence (NICE) published guidance on the use of pirfenidone (Esbriet® , Roche) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in 2013. NICE decided to review existing guidance following publication of an additional clinical trial, and invited the manufacturer of pirfenidone to submit evidence of its clinical and cost effectiveness for the treatment of mild to moderate IPF when compared with best supportive care (BSC) or nintedanib; nintedanib was a comparator only for moderate IPF...
October 22, 2018: PharmacoEconomics
Werner B F Brouwer
No abstract text is available yet for this article.
October 17, 2018: PharmacoEconomics
Christopher McCabe
No abstract text is available yet for this article.
October 17, 2018: PharmacoEconomics
Joanna Picot, Neelam Kalita, Wendy Gaisford, Petra Harris, Oluchukwu Onyimadu, Keith Cooper
Clinical and cost-effectiveness evidence on fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer was submitted to the single technology appraisal process of the National Institute for Health and Care Excellence by the manufacturer of fulvestrant. The Southampton Health Technology Assessments Centre was commissioned by the National Institute for Health and Care Excellence as an independent Evidence Review Group to critique the company's submitted evidence. Fulvestrant was compared directly with anastrozole in two randomised controlled trials and was compared indirectly by means of a network meta-analysis with anastrozole, letrozole and tamoxifen...
October 17, 2018: PharmacoEconomics
Tosin Lambe, Rui Duarte, James Mahon, Sarah Nevitt, Janette Greenhalgh, Angela Boland, Sophie Beale, Eleanor Kotas, Joanne McEntee, Ian Pomeroy
As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Merck to submit evidence for the clinical and cost effectiveness of cladribine tablets (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Rapidly evolving severe (RES) and sub-optimally treated (SOT) RRMS were specified by the National Institute for Health and Care Excellence as subgroups of interest. The Liverpool Reviews and Implementation Group at the University of Liverpool was the Evidence Review Group...
October 16, 2018: PharmacoEconomics
Richard Perry, George Braileanu, Thomas Palmer, Paul Stevens
Asthma is a chronic respiratory disease that is widespread throughout the US population and disproportionately affects children. This literature review aimed to identify recent information regarding the economic burden of pediatric asthma in the US. MEDLINE, EMBASE, Econlit, and PsycINFO databases and gray literature sources were searched from January 2012 to January 2018 to capture relevant publications. Publications reporting on healthcare resource utilization and/or healthcare costs of pediatric asthma were included (n = 8)...
October 13, 2018: PharmacoEconomics
Renske J Hoefman, Job van Exel, Werner B F Brouwer
BACKGROUND: Interventions in health care often not only have an effect on patients, but also on their informal caregivers. Caregiving can have a profound impact on the health and wellbeing of carers. Ignoring these spillovers in economic evaluations risks labelling interventions mistakenly as cost-effective, at the expense of informal caregivers. OBJECTIVE: This paper investigates willingness-to-accept (WTA) values for an hour of informal care, corrected for positive and negative impacts of informal care, to facilitate the inclusion of informal care hours on the cost side of economic evaluations without double-counting spillover effects...
October 9, 2018: PharmacoEconomics
Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, Kath Wright, Robert Hodgson
The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ceritinib (Zykadia® , Novartis) to submit evidence on the clinical and cost effectiveness of the drug, as a first-line treatment for adults with anaplastic lymphoma kinase (ALK)-positive (+) advanced non-small-cell lung cancer (NSCLC), as part of the Institute's single technology appraisal (STA) process. The CRD (Centre for Reviews and Dissemination) and CHE (Centre for Health Economics) Technology Assessment Group at the University of York was commissioned to act as the Evidence Review Group (ERG)...
October 8, 2018: PharmacoEconomics
Sandy Tubeuf, Eirini-Christina Saloniki, David Cottrell
OBJECTIVE: This article presents alternative parental health spillover quantification methods in the context of a randomised controlled trial comparing family therapy with treatment as usual as an intervention for self-harming adolescents, and discusses the practical limitations of those methods. METHODS: The trial followed a sample of 754 participants aged 11-17 years. Health utilities are measured using answers to the EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) for the adolescent and the Health Utility Index (HUI2) for one parent at baseline, 6 and 12 months...
October 8, 2018: PharmacoEconomics
Sabine E Grimm, Nigel Armstrong, Bram L T Ramaekers, Xavier Pouwels, Shona Lang, Svenja Petersohn, Rob Riemsma, Gillian Worthy, Lisa Stirk, Janine Ross, Jos Kleijnen, Manuela A Joore
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb) of nivolumab (Opdivo® ) to submit evidence of its clinical and cost effectiveness for metastatic or unresectable urothelial cancer. Kleijnen Systematic Reviews Ltd, in collaboration with Maastricht University Medical Centre+, was commissioned to act as the independent Evidence Review Group (ERG), which produced a detailed review of the evidence for the clinical and cost effectiveness of the technology, based on the company's submission to NICE...
October 6, 2018: PharmacoEconomics
Yun-Kyung Kim, Joon Young Song, Hyeongap Jang, Tae Hyun Kim, Heejo Koo, Lijoy Varghese, Euna Han
INTRODUCTION: Trivalent influenza vaccines (TIVs) are currently reimbursed for subjects aged ≥ 65 years and children between 6 and 59 months of age under a national immunization program in South Korea. Quadrivalent influenza vaccines (QIVs) are expected to address the potential problem of influenza B-lineage mismatch for TIVs. OBJECTIVE: The objective of this analysis was to compare the cost effectiveness of QIV versus TIV in children aged 6-59 months and older adults ≥ 65 years of age in South Korea...
September 25, 2018: PharmacoEconomics
Paul Tappenden, Emma Simpson, Jean Hamilton, Daniel Pollard, Mark Clowes, Eva Kaltenthaler, David Meiklejohn, Nick Morley
As part of its Single Technology Appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the clinical effectiveness and cost effectiveness of ibrutinib for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). The School of Health and Related Research Technology Assessment Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company's submission to NICE...
September 24, 2018: PharmacoEconomics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"